Saturday 17 October 2026
Export NEUP’s income statement to Excel — free account
Neuphoria Therapeutics Inc.
NEUP Healthcare Biotechnology
Neuphoria Therapeutics Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.2 million, down 92.5% from fiscal 2025. In the quarter to June 2026, revenue fell 107.3%, EPS grew 83.6% and free cash flow grew 133.9%, each against the same quarter a year earlier.
3.30
0.01
−0.30%
Follow NEUP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
2.68 | 9.03 | 13.91 | 27.33 | |
Current Ratio |
2.72 | 9.04 | 14.31 | 27.85 | |
Net Debt/EBITDA |
2.50 | 5.71 | 18.59 | 3.04 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.38 | (3.45) | 6.61 | (0.25) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.49 | 0.36 | 0.38 | 0.27 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.69) | (1.42) | (0.62) | 0.28 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.69) | (1.42) | (0.62) | 0.28 | |
Cash per Share |
6.11 | 4.91 | 3.59 | 4.52 | |
Shareholders Equity per Share |
5.57 | 6.55 | 5.44 | 5.60 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.57 | 6.55 | 5.44 | 5.60 | |
Free Cash Flow |
(3.79) | (6.44) | (3.34) | 1.21 | |
Working Capital |
8.83 | 20.80 | 20.14 | 20.31 | |
Net Current Asset Value |
(0.88) | 16.49 | 16.27 | 16.96 | |
| Other line items | |||||
Average Receivables |
0.06 | 0.57 | 0.81 | 0.41 | |
Average Payables |
1.35 | 1.03 | 0.69 | 0.77 | |
Average Assets |
25.13 | 27.38 | 32.76 | 28.65 | |
Average Common Equity |
14.79 | 21.72 | 27.71 | 21.80 |
Columns are period end dates · fundamentals updated 2 Oct 2026